Catalent Inc (NYSE:CTLT) – Equities researchers at William Blair boosted their FY2018 earnings estimates for Catalent in a report released on Wednesday. William Blair analyst J. Kreger now expects that the company will earn $1.52 per share for the year, up from their prior forecast of $1.43. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.63 EPS, Q2 2019 earnings at $0.38 EPS, Q3 2019 earnings at $0.45 EPS, Q4 2019 earnings at $0.67 EPS and FY2019 earnings at $1.76 EPS.
Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Catalent from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Royal Bank of Canada initiated coverage on shares of Catalent in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price target on the stock. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. Piper Jaffray Companies increased their price target on shares of Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. Finally, Morgan Stanley upgraded shares of Catalent from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $29.00 to $48.00 in a research note on Thursday, September 21st. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $44.44.
Catalent (CTLT) opened at $43.00 on Friday. The company has a market cap of $5,712.94, a P/E ratio of 30.07, a price-to-earnings-growth ratio of 2.73 and a beta of 1.41. Catalent has a one year low of $25.51 and a one year high of $43.39. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm’s revenue was up 23.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.16 earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio grew its position in shares of Catalent by 1,441.4% during the third quarter. Public Employees Retirement System of Ohio now owns 41,156 shares of the company’s stock worth $1,643,000 after acquiring an additional 38,486 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Catalent by 59.0% during the third quarter. GSA Capital Partners LLP now owns 52,972 shares of the company’s stock worth $2,115,000 after acquiring an additional 19,661 shares during the last quarter. Iguana Healthcare Management LLC purchased a new position in shares of Catalent during the third quarter worth approximately $1,198,000. Colony Group LLC purchased a new position in shares of Catalent during the third quarter worth approximately $2,543,000. Finally, Neuberger Berman Group LLC grew its position in shares of Catalent by 77.3% during the third quarter. Neuberger Berman Group LLC now owns 23,025 shares of the company’s stock worth $919,000 after acquiring an additional 10,036 shares during the last quarter. Institutional investors and hedge funds own 99.37% of the company’s stock.
In other news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Tuesday, November 21st. The shares were acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. Company insiders own 1.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “FY2018 Earnings Estimate for Catalent Inc (CTLT) Issued By William Blair” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/fy2018-earnings-estimate-for-catalent-inc-ctlt-issued-by-william-blair.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.